Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
- First dose level rated as safe by independent Data Safety Monitoring Board
- Second dose level to be administered according to plan
- THE001 designed as targeted tumor treatment independent of specific
- molecular targets or tumor subtypes
Munich, Germany – February 6, 2024 – Thermosome, a drug development company specializing in targeted tumor therapies, today announced that it received clearance by the independent Data Safety Monitoring Board (DSMB) to proceed as planned with the dose escalation in its ongoing Phase I trial of its lead program THE001. The first dose level was safe and well tolerated as assessed by the DSMB.